Oesophageal Cancer Clinical and Molecular Stratification Study (OCCAMS): A prospective multicentre trial to determine predictive and prognostic biomarkers and therapeutic targets for Oesophageal and Junctional Adenocarcinoma
Cancers that occur at the junction between the oesophagus (gullet) and the stomach are called gastro oesophageal junction (GOJ) adenocarcinomas. They are 6 times more common than they were 30 years ago and have a very poor outcome (only 1 in 5 patients will survive five years). We have previously developed a new way of determining how advanced a patient’s GOJ adenocarcinoma is (what we call staging) using both the physical features determined by the radiology tests and the molecular features of the cancer. This system works significantly better than the existing way we stage these cancers. However this new system was developed using patients who had already had their surgery. We now want to test it on patients at the beginning of their treatment- or what we term prospectively. The patients management will not differ from current practice but as well as looking at the features used for staging at the moment we will also record our new system in parallel. We will also test samples of the cancer which are already routinely taken for the molecular changes we think will predict survival. After this patients will undergo the standard treatment at each of the centres involved. It will then be possible to determine both how practical our new system is and how good it is at predicting survival. We will be running this prospective trial in multiple hospitals across the country to ensure that our system is broadly applicable.If we can prove that our revised staging system using both the physical features of the tumour and the molecular changes can accurately predict outcome this will allow us to give far better information to our patients about their chance of a cure but also it will also allow treatments to be targeted at those who will benefit the most.
|Sponsor||Cambridge University Hospitals NHS Foundation Trust|
|Proposed End Date||30/10/2021|
|Study Run through CRF?||No|
|Target number of patients agreed to recruit||100|
|Recruitment so far||199|